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ABSTRACT
Background Single nucleotide polymorphisms (SNPs)
rs429358 (ε4) and rs7412 (ε2), both invoking changes in
the amino-acid sequence of the apolipoprotein E (APOE)
gene, have previously been tested for association with
multiple sclerosis (MS) risk. However, none of these
studies was sufﬁciently powered to detect modest effect
sizes at acceptable type-I error rates. As both SNPs are
only imperfectly captured on commonly used microarray
genotyping platforms, their evaluation in the context of
genome-wide association studies has been hindered until
recently.
Methods We genotyped 12 740 subjects hitherto not
studied for their APOE status, imputed raw genotype
data from 8739 subjects from ﬁve independent genome-
wide association studies datasets using the most recent
high-resolution reference panels, and extracted genotype
data for 8265 subjects from previous candidate gene
assessments.
Results Despite sufﬁcient power to detect associations
at genome-wide signiﬁcance thresholds across a range of
ORs, our analyses did not support a role of rs429358 or
rs7412 on MS susceptibility. This included meta-analyses
of the combined data across 13 913 MS cases and
15 831 controls (OR=0.95, p=0.259, and OR 1.07,
p=0.0569, for rs429358 and rs7412, respectively).
Conclusion Given the large sample size of our
analyses, it is unlikely that the two APOE missense SNPs
studied here exert any relevant effects on MS
susceptibility.
INTRODUCTION
Multiple sclerosis (MS), the most common chronic
inﬂammatory disease of the central nervous
system, is likely caused by interplay of environ-
mental and genetic factors. Recent genome-wide
association studies (GWAS) have identiﬁed almost
60 putative risk loci apart from a well-established
association with the human leukocyte antigen
region on chromosome 6p21 (eg, refs.1–3). Despite
this recent progress, it has been estimated that
approximately 80% or more of the genetic variance
remains unexplained by the currently known loci.3
The failure to decipher the full genetic spectrum
of MS susceptibility may in part be due to incom-
plete coverage of the genome by the available
GWAS arrays. Along these lines, two single nucleo-
tide polymorphisms (SNPs) frequently tested for
association with MS risk in the pre-GWAS era,
that is, rs429358 (a.k.a. ‘ε4’) and rs7412 (‘ε2’) in
encoding apolipoprotein E (APOE), are absent from
most GWAS genotyping platforms. Thus, these
two APOE SNPs could not be directly assessed in
previous MS GWAS and GWAS meta-analyses. The
most recent release of whole-genome sequence
data from the 1000 Genomes Project now makes it
possible to impute genotypes at both sites for data
from most GWAS genotyping platforms.
The investigation of APOE, the single most
important risk locus for Alzheimer ’s disease, in
MS has been motivated by reports of genetic
linkage to the APOE-containing region on chromo-
some 19q13 (eg, ref.4) as well as by its functional
role in lipid transport, immunoregulation, neuro-
plasticity and repair mechanisms.5 However, APOE
association studies in MS have yielded mostly
negative results to date with some studies report-
ing signiﬁcant effects while most others were
unable to conﬁrm these associations. These incon-
sistencies can at least in part be attributed to small
sample sizes of the individual datasets. As a
matter of fact, none of the previously performed
APOE association studies in MS included more
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than 450 cases (see supplementary table S1 for an overview of
study-speciﬁc sample sizes). Even two previous meta-analyses
combining published data6 7 were limited in power to detect
modest effects (ie, ORs at or below 1.2) at acceptable type-1
error rates, eg, at a genome-wide signiﬁcance threshold (typic-
ally deﬁned as α=5×10−8).
To provide a more conclusive assessment of the potential
association between the two most commonly studied APOE
SNPs and MS susceptibility in populations of European
descent, we performed a large-scale association study of
rs429358 and rs7412 using MS risk as outcome. To this end, we
collected and genotyped 12 740 subjects hitherto not studied
for their APOE status, imputed raw genotype data from 8739
subjects from ﬁve independent GWAS datasets using the most
recent high-resolution reference panels, and extracted genotype
data for 8265 subjects from previous candidate gene assess-
ments to arrive at an overall samples size of up to 13 913 MS
cases and 15 831 controls.
SUBJECTS AND METHODS
The following section only provides a brief summary of the
methods applied to our study. A more detailed description can
be found in the supplementary material.
Literature search and data abstraction
Genetic association studies investigating the role of APOE on
MS susceptibility in populations of European descent were
identiﬁed by a search of NCBI’s PubMed database and via
inspecting cross-references in related publications. Only inde-
pendent case-control studies investigating the association of
APOE rs429358 and/or rs7412 with MS risk that were pub-
lished in peer-reviewed journals in English and available until
1st July 2012 were considered. Next, demographic details and
genotype summary data were extracted from eligible publica-
tions. Hardy-Weinberg equilibrium (HWE) testing in controls
and association analyses of rs429358 and rs7412 per dataset
were performed using Pearson’s χ2 test implemented in R
language.
GWAS analysis
We applied for and obtained raw genotypes for three previously
published GWAS, below referred to as ‘International Multiple
Sclerosis Genetics Consortium (IMSGC)’,1 ‘GeneMSA’,8 and
‘ANZgene’.2 Following pre-imputation QC ﬁltering, IMSGC
comprised 926 MS and 2319 control samples, GeneMSA 986
MS and 902 control samples (across three datasets from the
US, Switzerland and the Netherlands), and ANZgene 1618 MS
and 1988 control samples. Imputation of the 19q13 region
including the uncovered SNPs rs429358 and rs7412 was based
on ‘1000GP_hg19_Jun2011_PhaseI’ data panels using the
IMPUTE programme V.2.0 (http://mathgen.stats.ox.ac.uk/
impute/impute_v2.html). To estimate sample-speciﬁc additive
ORs, association analysis was performed using frequentist and
expectation maximization models adjusting for sex, population
stratiﬁcation as well as genotype uncertainty during the imput-
ation process.
Direct genotyping
Subjects: This arm of the study included 6741 MS cases and
5999 healthy controls of self-reported European descent from
Germany, France and Spain that were not previously assessed
for rs429358 and rs7412.
Genotyping: Genotypes in all German samples were deter-
mined by Sanger sequencing using the BigDye terminator v3.1
sequencing kit, resolved on an ABI3730XL genetic analyser
(Applied Biosystems). Raw sequences were analysed with
SeqMan II V.8.0.2 (DNASTAR). The French and the Spanish
samples were genotyped using allelic discrimination assays
based on TaqMan chemistry (Applied Biosystems).
Association analysis: HWE in controls was tested using
Pearson’s χ2 as implemented in PLINK V.1.07 (http://pngu.mgh.
harvard.edu/purcell/plink/). Logistic regression without and
with adjustment for age and/or sex (where available in >90%
of subjects) was performed in PLINK using an additive trans-
mission model.
Meta-analysis
Meta-analyses were based on random-effects models including
all published and newly generated datasets. In addition, we per-
formed meta-analyses after stratiﬁcation for published and
newly generated datasets. Sensitivity analyses were performed
after exclusion of datasets in which control subjects showed
HWE violations (p<0.05). Between-study heterogeneity was
quantiﬁed using the I2 metric. Evidence for small-study effects,
which can be indicative of publication or selective reporting
biases, was assessed using a modiﬁed regression test.8 All ana-
lyses were performed in R, using packages ‘HardyWeinberg’,
V.1.4 and ‘rmeta’, V.2.16. All reported meta-analysis p values are
two-tailed. Statistical signiﬁcance was deﬁned at a genome-
wide level (p<5×10−8), while a trend for association was set to
p<1×10−4.
RESULTS
Overall, our study comprised 13 913 cases and 15 831 controls
across 29 individual datasets for rs429358, and 13 202 cases and
15 258 controls across 26 datasets for rs7412 (see
supplementary ﬁgure S1 and tables S1–S3 for details). In the
combined analyses, we had approximately 99% and 72% power
to detect an OR of 1.20 at a genome-wide signiﬁcance thresh-
old (α=5×10−8) for rs429358 and rs7412, respectively. In total,
our study exceeded the above mentioned recent meta-analyses6 7
across 58316 and 7706 Caucasian subjects7 by ∼23 900 and
22 000 subjects, respectively.
Meta-analyses of rs429358 and rs7412 across all datasets did
not reveal signiﬁcant evidence for association and yielded effect
size estimates close to the null (rs429358: OR=0.95, p=0.259,
rs7412: OR 1.07, p=0.0569, ﬁgure 1) with moderate and no evi-
dence for heterogeneity, respectively (rs429358: I2=35, rs7412:
I2=0). Stratiﬁed analyses testing on published, GWAS, and
newly genotyped datasets for rs429358 yielded similar results
(ﬁgure 1 and see supplementary table S4). There was no evi-
dence for small-study effects, as a measure of potential publica-
tion bias, for the published data on rs429358 (p=0.942). For
rs7412, meta-analysis results across published datasets yielded a
relatively pronounced OR of 1.19 (p=0.0263), and no evidence
for heterogeneity (I2=0, see supplementary table S4). However,
in this stratum the regression test also showed signiﬁcant evi-
dence for small-study effects (p=0.0047), which could indicate
the presence of publication or selective reporting bias. In this
context, it is of note that two publications reported data on
rs429358 but not rs7412 (see supplementary table S1),
although those data had been generated in the respective
studies. Along these lines, analysis of rs7412 stratiﬁed for
GWAS and newly genotyped datasets showed only non-
signiﬁcant effect estimates close to the null (OR=0.96,
p=0.579, and OR=1.04, p=0.616, respectively, ﬁgure 1 and see
supplementary table S4). Accordingly, combining all available
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data for rs7412 led to an overall non-signiﬁcant meta-analysis
result for rs7412 (OR 1.07, p=0.0569; ﬁgure 1).
DISCUSSION
Upon combining genotype data from more than 29 000 indivi-
duals we failed to detect any noteworthy genetic effects of
two commonly studied missense SNPs in APOE on MS risk.
Given its sample size and inherent statistical power, our study
compellingly suggests that even modest effects of rs429358 and
rs7412 on MS risk are unlikely. The fact that previous studies
yielded only inconclusive results can most likely be attributed
to a lack in power, a problem overcome by the present analysis.
Despite the large sample size, we cannot exclude that APOE
rs429358 and rs7412 exert smaller genetic effects than assumed
here. For instance, the smallest effect size estimate to reach
genome-wide signiﬁcance in the recent MS GWAS3 was 1.09.
Given the allele frequencies at APOE rs429358 and rs7412, this
would require a total of 88 000 and 140 000 subjects, respect-
ively, to yield ∼80% power to detect such effect sizes at a
genome-wide signiﬁcance threshold. While our study lacked
power to detect such minor effects, we do not even observe a
trend for association in the present datasets making the exist-
ence of any role of the investigated APOE SNPs highly unlikely.
Another limitation of our study pertains to the lack of effect-
ively controlling for hidden population substructure in a sub-
stantial number of datasets. However, the results of our GWAS
meta-analyses, which were adjusted for population substruc-
ture, yielded results that were very similar in comparison to the
meta-analysis results of the newly genotyped datasets.
Similarly, due to the lack of access to individual-level genotype
and covariate data, we were not able to adjust the association
results from the published datasets for age at examination and
sex. However, the results from other datasets of our study,
where inclusion of age and sex as covariates in the association
analysis was possible, do not suggest an appreciable effect of
these covariates on the association with disease risk.
Furthermore, we only assessed the potential association of MS
with the functional variants rs429358 and rs7412. Thus, we
cannot exclude that other variants in this region, which are in
weak or no linkage disequilibrium with those two SNPs, exert
an effect on MS risk. However, this is unlikely given the col-
lectively negative results in recent MS GWAS1 2 and GWAS
meta-analyses,9 10 that have captured a substantial fraction of
the genetic variation at this locus, except for SNPs rs429358
and rs7412 which could not be effectively imputed until very
recently. Finally, our study was restricted to assessing the inﬂu-
ence of the two APOE SNPs on MS susceptibility only. A pos-
sible inﬂuence of these SNPs on other MS-relevant traits, such
as disease progression or MRI changes, cannot be excluded.
Studies investigating the association of APOE and these out-
comes in MS are numerous and typically show contradicting
results, possibly due to small sample sizes. Despite these
caveats, it is interesting to note that the largest studies on
APOE as predictor of MS severity, cognition, or brain atrophy
published to date do not suggest any noteworthy effects (see
ref.11 as example and for an overview of other related studies).
In summary, our study, which combines de novo genotyping
results from multiple populations, imputed GWAS data, and
systematically collated evidence from the literature does not
support a role of the two most commonly studied SNPs in
APOE in modifying susceptibility for MS in populations of
European descent.
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